A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties.
The glycolipid alpha-galactosylceramide (alphaGalCer) has immunomodulatory properties, which have been exploited to combat cancer, chronic inflammatory diseases, and infections. However, its poor solubility makes alphaGalCer a suboptimal compound for in vivo applications. In this study, a pegylated derivative of alphaGalCer is characterized, which exhibits improved physical and biological properties. The new compound, alphaGalCerMPEG, is water-soluble and retains the specificity for the CD1d receptor of alphaGalCer. The in vitro stimulatory properties on immune cells (e.g., dendritic cells and splenocytes) are maintained intact, even when tested at a 33-fold lower concentration of the active moiety than alphaGalCer. NK cells isolated from mice treated with alphaGalCerMPEG also had stronger cytotoxic activity on YAC-1 cells than those obtained from animals receiving either alphaGalCer or CpG. Intranasal immunization studies performed in mice showed that alphaGalCerMPEG exerts stronger adjuvant activities than the parental compound alphaGalCer when tested at 0.35 vs 11.7 nM/dose. Coadministration of beta-galactosidase with alphaGalCerMPEG resulted not only in high titers of Ag-specific Abs in serum (i.e., 1:512,000), but also in the stimulation of stronger Th2 and secretory IgA responses, both at local and remote mucosal effector sites (i.e., nose, lung, and vagina). The new synthetic derivative alphaGalCerMPEG represents a promising tool for the development of immune interventions against infectious and noninfectious diseases.
Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Thomas
T
Ebensen
Claudia
C
Link
Peggy
P
Riese
Kai
K
Schulze
Michael
M
Morr
Carlos A
CA
Guzmán
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology; D000281:Administration, Intranasal; D000818:Animals; D000918:Antibody Specificity / Q000187:drug effects / Q000276:immunology; D000941:Antigens / Q000276:immunology / Q000494:pharmacology; D002460:Cell Line; D002908:Chronic Disease; D003713:Dendritic Cells / Q000276:immunology; D005699:Galactosylceramides / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D007114:Immunization; D007070:Immunoglobulin A / Q000276:immunology; D007155:Immunologic Factors / Q000276:immunology* / Q000494:pharmacology; D007239:Infections / Q000276:immunology / Q000628:therapy; D007249:Inflammation / Q000276:immunology / Q000628:therapy; D051379:Mice; D009092:Mucous Membrane / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D009841:Oligonucleotides / Q000276:immunology / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000737:chemistry / Q000494:pharmacology; D012995:Solubility; D013154:Spleen / Q000276:immunology; D001616:beta-Galactosidase / Q000276:immunology / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D000941:Antigens; D005699:Galactosylceramides; D007070:Immunoglobulin A; D007155:Immunologic Factors; D009841:Oligonucleotides; C493154:alpha-galactosylceramide; D011092:Polyethylene Glycols; D001616:beta-Galactosidase